Head-To-Head Comparison: Oncobiologics (ONS) vs. Charles River Laboratories Intl. (CRL)

Oncobiologics (NASDAQ: ONS) and Charles River Laboratories Intl. (NYSE:CRL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability.

Valuation & Earnings

This table compares Oncobiologics and Charles River Laboratories Intl.’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oncobiologics $3.81 million 7.84 -$38.84 million N/A N/A
Charles River Laboratories Intl. $1.68 billion 3.06 $154.76 million $4.10 26.49

Charles River Laboratories Intl. has higher revenue and earnings than Oncobiologics.

Analyst Recommendations

This is a summary of recent ratings and target prices for Oncobiologics and Charles River Laboratories Intl., as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics 0 2 1 0 2.33
Charles River Laboratories Intl. 0 6 4 0 2.40

Oncobiologics currently has a consensus target price of $9.00, indicating a potential upside of 669.23%. Charles River Laboratories Intl. has a consensus target price of $113.80, indicating a potential upside of 4.79%. Given Oncobiologics’ higher probable upside, equities analysts clearly believe Oncobiologics is more favorable than Charles River Laboratories Intl..

Profitability

This table compares Oncobiologics and Charles River Laboratories Intl.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oncobiologics -1,017.57% N/A -226.21%
Charles River Laboratories Intl. 10.72% 26.58% 8.92%

Risk and Volatility

Oncobiologics has a beta of -0.46, meaning that its stock price is 146% less volatile than the S&P 500. Comparatively, Charles River Laboratories Intl. has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.

Institutional and Insider Ownership

17.9% of Oncobiologics shares are owned by institutional investors. Comparatively, 96.7% of Charles River Laboratories Intl. shares are owned by institutional investors. 33.5% of Oncobiologics shares are owned by company insiders. Comparatively, 2.2% of Charles River Laboratories Intl. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Charles River Laboratories Intl. beats Oncobiologics on 9 of the 12 factors compared between the two stocks.

Oncobiologics Company Profile

Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company’s other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company’s clients’ manufacturing activities.

Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply